Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ5 | P48544 | 7/20 | 0.68 |
| ▸ | KCNJ3 | P48549 | 7/20 | 0.68 |
| ▸ | KCNJ6 | P48051 | 3/20 | 0.56 |
| ▸ | CLK2 | P49760 | 1/20 | 0.54 |
| ▸ | PRKX | P51817 | 1/20 | 0.54 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.54 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.54 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.54 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.51 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15741746 | 0.84 | KCNJ5 (0.68) | KCNJ5KCNJ3KCNJ6CLK2PRKX | |
| SCHEMBL4685295 | 0.83 | KCNJ5 (0.66) | KCNJ5KCNJ3KCNJ6CLK2PRKX | |
| SCHEMBL30502369 | 0.81 | KCNJ5 (0.68) | KCNJ5KCNJ3KCNJ6CLK2PRKX | |
| SCHEMBL15741788 | 0.80 | KCNJ5 (0.65) | KCNJ5KCNJ3KCNJ6CLK2PRKX | |
| SCHEMBL95063 | 0.78 | RAB9A (0.56) | NPC1RAB9AALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL16887459 | 0.78 | ALDH1A1 (0.76) | KCNJ5KCNJ3KCNJ6CLK2PRKX | |
| SCHEMBL5852192 | 0.77 | EPHX2 (0.76) | NPC1RAB9AALDH1A1LMNAPOLB | |
| SCHEMBL2184203 | 0.76 | RORA (0.71) | KCNJ5KCNJ3NPC1RAB9AANO1 | |
| SCHEMBL19576522 | 0.76 | KCNJ5 (0.56) | KCNJ5KCNJ3KCNJ6CLK2PRKX | |
| SCHEMBL31729852 | 0.75 | KCNJ5 (0.74) | KCNJ5KCNJ3KCNJ6CLK2PRKX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| CN-101489555-A | Nf-kappa | OTSUKA PHARMA CO LTD (JP) | 2009-07-22 | — | — | CN | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | KCNJ5 2576/4885KCNJ3 2957/4885KCNJ6 2671/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | KCNJ5 1616/4885KCNJ3 2532/4885KCNJ6 1293/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | KCNJ5 1616/4885KCNJ3 2532/4885KCNJ6 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.